Profitability Of Infused Biologics For Hospitals And Physician Practices: Case Study Of Keytruda Authors: James C. Robinson james.robinson@berkeley.edu, Ari Kosorukov, Mark Thomson, and Christopher M. Whaley

https://www.healthaffairs.org/doi/10.1377/hlthaff.2026.00334?utm_campaign=august%202026%20issue&utm_medium=email&_hsenc=p2ANqtz-9JC9qxuXRh1tTg6riilesK8-tWuBwzmhMBfbEzlGBJxgQ3N_CwHaqrqQ4cDO2kZZHHP5aDOCrEHKP_8e-cKBR77ulkOg&_hsmi=435825762&utm_source=well%20read A new analysis found that private insurer spending on Keytruda has surged alongside use of the drug, with hospitals, particularly those participating in the 340B program, earning substantially higher reimbursement margins than community physician practices.